Table 2.

Renal Outcomes

Outcome	Valsartan or enalapril	Sacubitril/valsartan	Treatment Effect (95% CI)	P-interaction
Renal Composite, no. events/no.participants (%)
Combined	123/6601 (1.9)	70/6594 (1.1)	0.56 (0.42–0.75)	0.50
PARAGON-HF	64/2389 (2.7)	33/2407 (1.4)	0.50 (0.33–0.77)
PARADIGM-HF	59/4212 (1.4)	37/4187 (0.9)	0.62 (0.41–0.93)
>50% decline in eGFR, no. events/no.participants (%)				0.11
Combined	102/6601 (1.5)	59/6594 (0.9)	0.57 (0.41–0.78)
PARAGON-HF	60/2389 (2.5)	27/2407 (1.1)	0.44 (0.28–0.69)
PARADIGM-HF	42/4212 (1.0)	32/4187 (0.8)	0.75 (0.48–1.19)
End-stage renal disease, no. events/no.participants (%)				0.80
Combined	28/6601 (0.4)	15/6594 (0.2)	0.52 (0.28–0.98)
PARAGON-HF	12/2389 (0.5)	7/2407 (0.3)	0.58 (0.23–1.47)
PARADIGM-HF	16/4212 (0.4)	8/4187 (0.2)	0.49 (0.21–1.13)

P-interaction tests for effect modification according to parent study (PARAGON-HF versus PARADISE-HF).